NCT04072679View on ClinicalTrials.gov

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

November 11, 2020

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Sintilimab+IBI305

It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.

Trial Locations (1)

100021

National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter